Impact of the PIK3CA mutation on breast cancer

Bruno Franco Santoro and Mónica Casalnuovo

SAP Health and Policy, 2024

Abstract: Breast cancer was a health priority both globally and in Argentina, where it was the leading cause of death from tumours in women. Its molecular and genetic understanding has led to advances in diagnosis, prognosis and treatment. The luminal subtype, characterised by hormone receptors, and the PIK3CA gene mutation, involved in the PI3K/Akt/mTOR pathway, were highlighted as being associated with greater tumour aggressiveness and resistance to therapies. In Argentina, studies have shown a high prevalence of this mutation, prompting the use of targeted therapies such as Alpelisib. This personalised approach has improved the stratification and clinical management of the disease.

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://southam.pub/journals/files/shp/shp2024105en.pdf (application/pdf)
https://southam.pub/journals/files/shp/shp2024105es.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cwf:shpart:shp2024105

DOI: 10.56294/shp2024105

Access Statistics for this article

More articles in SAP Health and Policy from South American Publishing
Bibliographic data for series maintained by South American Publishing Journals Manager ().